drugset / Trial / NCT04905277
Atenolol for the Prevention of Osteoporosis (APO)
Phase 2
Completed
420 enrolled
Sundeep Khosla, M.D.
Columbia University · collabMaineHealth · collabUniversity of California, San Francisco · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss at the lower back and hip in postmenopausal women.
Timeline
- Start
- 2021-07-27
- Primary completion
- 2026-02-02
- Completion
- 2026-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atenolol | Other / unclassified | 50 mg | — |
Indications
No indication recorded.